826
X.-Q. Lu¨ et al. / Journal of Organometallic Chemistry 691 (2006) 821–828
78.10; H, 5.56; N, 11.92%. Mp: 142–143 ꢁC. IR (KBr,
cmꢁ1): 1629 (vs), 1584 (s), 1535 (m), 1498 (s), 1385 (vs),
1365 (s), 1227 (w), 1139 (w), 1006 (w), 778 (w), 758 (m),
tion of CuCl2 (9 mg, 0.05 mmol) in EtOH (5 ml) was added
and the mixture kept stirring for 20 min. The resultant
clear brown solution was filtered and left to stand at room
temperature for several days to give black crystalline prod-
uct of 1 in 70% yield. Anal. Calc. for C46H36N6O2Cu: C,
71.91; H, 4.72; N, 10.94. Found: C, 72.22; H, 5.04; N,
10.79%. IR (KBr, cmꢁ1): 1595 (s), 1561 (vs), 1526 (s),
1475 (vs), 1435 (s), 1398 (m), 1377 (s), 1246 (w), 1212
(m), 1153 (w), 1064 (w), 1026 (w), 1006 (w), 980 (w), 850
(w), 791 (w), 757 (m), 706 (m), 659 (w), 589 (m), 513 (w),
481 (w). ES–MS (m/z): 769 (M+ ꢁ H).
3.1.2.2. [Cu(L2)2] (2). 2 was prepared using HL2
(41 mg, 0.1 mmol). Yield: 71%. Anal. Calc. for
C54H40N6O2Cu: C, 74.68; H, 4.64; N, 9.68. Found: C,
74.62; H, 5.14; N, 9.79%. IR (KBr, cmꢁ1): 1595 (m),
1560 (vs), 1526 (s), 1480 (vs), 1435 (s), 1380 (m), 1261
(w), 1225 (w), 1156 (w), 1084 (w), 1025 (w), 805 (w), 763
(m), 693 (m), 658 (w), 631 (w), 595 (w), 511 (w). ES–MS
(m/z): 869 (M+ ꢁ H).
1
699 (m), 573 (w), 509 (w). ES–MS (m/z): 354 (M+). H
NMR (CDCl3), d (ppm): 12.99 (s, 1H, –NH); 8.04 (d,
2H), 7.41 (m, 7H), 7.14 (t, 3H), 7.06 (t, 1H), 6.81 (d,
2H), 1.56 (s, 3H).
3.1.1.2. 5-Methyl-2-phenyl-4-[(2-naphthylamino)-phenylm-
ethylene]pyrazol-3(2H)-one (HL2). Ligand HL2 was
obtained by using a-naphthylamine (1.36 g), in 62%
(2.24 g) yield. Anal. Calc. for C27H21N3O: C, 80.37; H,
5.25; N, 10.41. Found: C, 80.34; H, 5.34; N, 10.29%. Mp:
175–176 ꢁC. IR (KBr, cmꢁ1): 1620 (vs), 1587 (s), 1535
(m), 1489 (s), 1460 (w), 1439 (w), 1393 (vs), 1321 (w),
1272 (w), 1250 (w), 1174 (w), 1145 (m), 1004 (w), 797
(m), 764 (m), 698 (w), 588 (w), 561 (w), 511 (w). ES–MS
1
(m/z): 404.3 (M+). H NMR (CDCl3), d (ppm): 13.32 (s,
–NH); 8.25 (d, 1H), 8.08 (d, 2H), 7.82 (d, 1H), 7.60 (m,
2H), 7.53 (m, 1H), 7.43 (t, 2H), 7.35 (m, 1H), 7.28 (m,
4H), 7.18 (t, 1H), 7.12 (t, 1H), 6.84 (d, 1H), 1.62 (s, 3H).
3.1.2.3. [Cu(L3)2] (3). 3 was prepared using HL3
(37 mg, 0.1 mmol). Yield: 67%. Anal. Calc. for
C48H40N6O2Cu: C, 72.39; H, 5.06; N, 10.55. Found: C,
72.52; H, 5.44; N, 10.79%. IR (KBr, cmꢁ1): 1595 (m),
1560 (vs), 1526 (s), 1477 (vs), 1438 (s), 1375 (m), 1220
(w), 1188 (w), 1064 (w), 1028 (w), 843 (w), 758 (m), 722
(w), 704 (w), 658 (w), 598 (w), 511 (w). ES–MS (m/z):
797 (M+ ꢁ H).
3.1.2.4. [Cu(L4)2] (4). 4 was prepared using HL4
(40 mg, 0.1 mmol) with 80% yield (0.78 g). Anal. Calc.
for C46H34N8O6Cu: C, 64.37; H, 3.99; N, 13.05. Found:
C, 64.82; H, 4.34; N, 12.79%. IR (KBr, cmꢁ1): 1597 (m),
1563 (vs), 1519 (s), 1479 (vs), 1436 (s), 1381 (m), 1340 (s),
1251 (w), 1217 (m), 1168 (w), 1107 (w), 1063 (w), 1011
(w), 983 (w), 867 (m), 784 (w), 758 (m), 714 (m), 655 (w),
609 (w), 573 (w), 435 (w). ES–MS (m/z): 859 (M+ ꢁ H).
3.1.1.3.
ene]pyrazol-3(2H)-one
5-Methyl-2-phenyl-4-[(2-o-tolyl)-phenylmethyl-
(HL3). Ligand HL3
was
obtained by using o-toluidine (1.29 g), Yield: 65%
(2.15 g). Anal. Calc. for C24H21N3O: C, 78.45; H, 5.76;
N, 11.44. Found: C, 78.23; H, 6.06; N, 11.14%. Mp: 173–
174 ꢁC. IR (KBr, cmꢁ1): 1626 (vs), 1585 (vs), 1537 (m),
1498 (s), 1463 (m), 1385 (vs), 1237 (w), 1188 (w), 1143
(m), 1051 (w), 1007 (m), 831 (w), 756 (s), 708 (w), 654
(w), 589 (w). ES–MS (m/z): 368 (M+). H NMR (CDCl3),
d (ppm): 12.88 (s, –NH); 8.06 (d, 2H), 7.43 (m, 6H), 7.29 (t,
1H), 7.19 (t, 2H), 7.03 (t, 1H), 6.88 (t,1H), 6.62 (d, 1H),
2.46 (s, 3H),1.63 (s, 3H).
1
3.1.1.4. 5-Methyl-2-phenyl-4-[(2-p-nitrophenylamino)-phe-
nylmethylene]-pyrazol-3(2H)-one (HL4). Ligand HL4
was obtained by using p-nitroaniline (1.30 g) and formic
acid (1 ml), the latter was added to ensure acidity of the
solution. Yield: 2.10 g (60%). Anal. Calc. for
C23H18N4O3: C, 69.35; H, 4.52; N, 14.07. Found: C,
69.50; H, 4.68; N, 14.14%. Mp: 202–203 ꢁC. IR (KBr,
cmꢁ1): 1644 (vs), 1581 (vs), 1522 (s), 1497 (vs), 1399 (s),
1372 (s), 1340 (vs), 1312 (s), 1235 (m), 1194 (w), 1141 (m),
1109 (m), 1051 (w), 1008 (w), 933 (w), 858 (w), 830 (s),
779 (m), 754 (s), 726 (m), 709 (m), 689 (m), 647 (w), 610
3.2. X-ray crystallography
Single crystals of 1 Æ EtOH, 3 and 4, obtained from
recystallization in CH2Cl2–EtOH (v/v, 1/2), of suitable
dimensions were mounted onto glass fibers for crystallo-
graphic analyses. All the intensity data were collected on
a Bruker SMART CCD diffractometer (Mo Ka radiation,
(m), 554 (w), 498 (w). ES–MS (m/z): 399 (M+). H NMR
k = 0.71073 A) in U and x scan modes. Structures were
1
˚
(CDCl3), d (ppm): 13.31 (s, 1H, –NH); 7.99 (m, 4H), 7.55
(m, 4H), 7.42 (m, 4H), 6.82 (d, 2H), 1.61 (s, 3H, –CH3).
solved by Patterson methods followed by difference Fou-
rier syntheses, and refined by full-matrix least-squares tech-
niques against F2 using SHELXTL [21a]. Except for atoms
belonging to disordered solvate molecules, all the non-
hydrogen atoms were refined with anisotropic thermal
parameters. The solvate EtOH molecule in 1 Æ EtOH was
disordered over two positions and were refined with frac-
tional site occupancy. Absorption corrections were applied
using SADABS [21b]. All hydrogen atoms were placed in cal-
culated positions and refined isotropically using a riding
3.1.2. Complexes 1–4
Complexes 1–4 were prepared by a similar procedure as
depicted by the synthesis of 1.
3.1.2.1. [Cu(L1)2] (1). The CH2Cl2 solution (5 ml) con-
taining HL1 (36 mg, 0.1 mmol) and Et3N (14 ll, 0.1 mmol)
was stirred for 10 min at room temperature, then the solu-